MiMedx Cuts $40M in Costs, Eliminates COO Role Amid Wound Care Slowdown
Event summary
- MiMedx Group, Inc. announced a restructuring initiative on April 16, 2026, eliminating the COO position held by Ricci Whitlow.
- The company plans to reduce annual operating expenses by approximately $40 million, with a one-time restructuring charge of $4 million in Q2 2026.
- The restructuring is driven by slower-than-expected recovery in the Wound Care business following a January 2026 Medicare reimbursement reduction.
- The Surgical business continues to grow and will receive additional investments.
The big picture
MiMedx's restructuring reflects broader challenges in the medical device sector, particularly around reimbursement changes and market recovery timelines. The company's decision to cut costs while doubling down on its Surgical business highlights a strategic pivot toward more resilient revenue streams. The $40 million expense reduction underscores the financial pressure faced by firms operating in the wound care space amid regulatory shifts.
What we're watching
- Market Recovery Pace
- The pace at which the Wound Care market recovers from the Medicare reimbursement cut will determine the necessity of further cost reductions.
- Execution Risk
- How effectively MiMedx implements the $40 million cost-cutting plan without disrupting its Surgical business growth.
- Strategic Focus
- Whether the company can sustain its Surgical business momentum while navigating the slower Wound Care market.
Related topics